Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01730937 · ClinicalTrials.gov registry record · Phase 3
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 193
- Enrollment target
NCT01730937 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 193 participants.
The verdict
NCT01730937, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 193 participants
- Enrollment target
Study Summary
This randomized phase III trial studies sorafenib tosylate and stereotactic body radiation therapy to see how well they work compared to sorafenib tosylate alone in treating patients with liver cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy may be able to send the radiation dose directly to the tumor and cause less damage to normal tissue. Giving sorafenib tosylate together with stereotactic body radiation therapy may kill more tumor cells.
Interventions
- DRUG Sorafenib
- RADIATION stereotactic body radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2013-04 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01730937
The ClinicalTrials.gov registry entry for NCT01730937 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT01730937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01730937 about?
NCT01730937 is a clinical study titled "Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer". This randomized phase III trial studies sorafenib tosylate and stereotactic body radiation therapy to see how well they work compared to sorafenib tosylate alone in treating patients with liver cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for c...
What is the current status of trial NCT01730937?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 193 participants. The study started on 2013-04. Estimated completion is 2025-09-04.
What interventions are being tested in trial NCT01730937?
The interventions under investigation include: Sorafenib (DRUG), stereotactic body radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT01730937?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.